Curbside ConsultMetformin Use in Decompensated Heart FailureBoyd, Alex PharmD*; Nawarskas, James PharmD, BCPS†Author Information From the *Virginia Commonwealth University School of Pharmacy, Richmond, Virginia; and †The University of New Mexico—College of Pharmacy, Albuquerque, New Mexico. Correspondence: James Nawarskas, PharmD, BCPS, University of New Mexico—College of Pharmacy, 2502 Marble NE, Albuquerque, NM 87131-0001. E-mail: [email protected]. Cardiology in Review: September-October 2008 - Volume 16 - Issue 5 - p 269-272 doi: 10.1097/CRD.0b013e3181846c53 Buy Metrics Abstract Metformin is associated with decreased mortality and morbidity in stable heart failure patients with diabetes mellitus type II. Diabetic heart failure patients with elevated systolic blood pressure are at increased risk for developing acute decompensated heart failure, which is often associated with decreased kidney function. Metformin-associated lactic acidosis is a rare but fatal side effect that may occur when kidney function is decreased. During acute decompensated heart failure, timely treatment may prevent the decrease in kidney function to the threshold associated with an increased risk of metformin-associated lactic acidosis. Metformin should not be withheld in diabetic patients with stable heart failure who do not have other risk factors for acute decompensated heart failure or lactic acidosis. © 2008 Lippincott Williams & Wilkins, Inc.